MENLO PARK, Calif., February 2, 2015 – Geron Corporation (Nasdaq:GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 17th Annual BIO CEO & Investor Conference in New York. The presentation is scheduled to occur on Monday, February 9, at 2:00 p.m. Eastern Time. A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website or at http://www.veracast.com/webcasts/bio/ceoinvestor2015/01119294643.cfm. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days. About Geron Geron is a clinical… Read more »
Shares of Geron closed last Friday at $3.18 . GERN has a 1-year high of $5.28 and a 1-year low of $1.39. The stock’s 50-day moving average is $3.21 and it’s 200-day moving average is $2.69.
On the ratings front, Geron (NASDAQ:GERN) has been the subject of a number of recent research reports. In a report issued on November 14, Piper Jaffray analyst Charles Duncan upgraded GERN to Buy, with a price target of $5, which reflects a potential upside of 57.2% from last closing price. Separately, on the same day, MLV & Co.’s George Zavoico maintained a Buy rating on the stock and has a price target of $4.25.
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.